Longitudinal dynamics and recovery of lymphocytes in patients with breast cancer receiving radiotherapy without chemotherapy after breast-conserving surgery: A second analysis of a phase III randomized trial of HYPOfractionation in BREAST radiotherapy for Chinese women (CHN HYPOBREAST)
In brief
Hypofractionated breast radiation had 6.5% moderate lymphopenia, versus 24.5%
Among 203 women treated with breast-conserving surgery and radiation without chemotherapy, moderate-or-worse lymphopenia was less common with hypofractionated than conventional radiation: 6.5% versus 24.5%. Lymphocyte counts took years to return to baseline, reaching it at 3 years after hypofractionated and 4 years after conventional treatment; whether faster recovery improves clinical outcomes remains unknown.
- Journal
- Therapeutic advances in medical oncology (Q1)
- Published
- 29 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Yu-Chun Song, Chao-Nan Zhang, Guang-Yi Sun, Xu-Ran Zhao, Si-Ye Chen, Zi-Han Qiu, et al.
- PMID
- 43036566
- DOI
- 10.1177/17588359261494276
Why clinicians should know about it
- Picked for Radiation Oncology (top studies of the week, 22 November 2026): Phase III RCT, supports hypofractionated breast RT
Abstract
BACKGROUND: Radiotherapy-induced lymphopenia (RIL) has been associated with inferior clinical outcomes in multiple solid tumors. However, the long-term dynamics and recovery of peripheral lymphocyte counts (PLCs) after radiotherapy remain poorly characterized. OBJECTIVES: To evaluate the longitudinal dynamics of PLCs in patients with breast cancer treated with radiotherapy (RT) without chemotherapy after breast-conserving surgery (BCS) and to identify the timepoint of recovery to pre-treatment levels. DESIGN: A secondary analysis of PLC dynamics was performed in selected patients enrolled in the prospective, multicenter, randomized phase III CHN-HYPOBREAST trial comparing hypofractionated RT (HFRT) with conventional fractionated RT (CFRT) after BCS. METHODS: This study included 203 patients. Among them, 96 were in the HFRT group and 107 were in the CFRT group. PLCs were measured at baseline (before any cancer treatment), pre-RT (after surgery but before RT), weekly during RT, and periodically up to 5 years after RT. Longitudinal PLC trends were analyzed using generalized linear mixed models. RESULTS: The pre-RT PLCs were comparable to baseline, and the PLCs gradually decreased during RT. In the HFRT and CFRT groups, the PLCs recovered to the baseline level 3 and 4 years after RT, respectively. Compared with the CFRT group, the HFRT group had a significantly higher mean nadir PLC (1.26 ± 0.42 × 109/L vs. 1.05 ± 0.32 × 109/L, P < 0.001) and a significantly lower ≥G2 lymphopenia rate (6.5% vs. 24.5%, P = 0.001). CONCLUSIONS: RT-induced lymphopenia in patients with breast cancer undergoing BCS without chemotherapy was generally mild. HFRT resulted in less severe lymphopenia than CFRT. However, the PLCs experienced a prolonged reduction period in both groups, recovering to baseline level 3 years after RT with HFRT and 4 years with CFRT. These findings provide additional evidence supporting the clinical use of HFRT and highlight the need for strategies to minimize RIL and promote lymphocyte recovery.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.